Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LDN-072
- Development stage
- Preclinical
- Lead developer
- Ladon Therapeutics
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
LDN-072 is an investigational oral peptide therapeutic being developed by Ladon Therapeutics. It is built upon the company's proprietary A3SMO (Artificial Amino Acid-based Small Molecule) platform, which utilizes advanced artificial amino acid chemistry to create first-in-class medicines. LDN-072 is designed to target A3SMO-related pathways to exert anti-inflammatory and anti-fibrotic effects. Currently in the preclinical stage, it is being explored for the treatment of various chronic conditions, including inflammatory bowel disease (IBD), chronic pancreatitis, and liver fibrosis, as well as obesity and other autoimmune diseases.
Beyond the preview
Go deeper on LDN-072.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LDN-072.